Aspire Biopharma Holdings, Inc. financial data

Symbol
ASBP, ASBPW on Nasdaq
Location
Estero, FL
Fiscal year end
31 December
Latest financial report
10-Q/A - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 15% % 340%
Debt-to-equity -118% % 83%
Return On Equity 269% % 123%
Return On Assets -1492% % -28727%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 107,477,178 shares
Common Stock, Shares, Outstanding 49,525,970 shares
Entity Public Float $87,000,000 USD 363%
Common Stock, Value, Issued $4,953 USD
Weighted Average Number of Shares Outstanding, Basic 49,525,970 shares 79%
Weighted Average Number of Shares Outstanding, Diluted 49,525,970 shares 79%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $207,899 USD 2870%
Selling and Marketing Expense $425,489 USD 2451%
General and Administrative Expense $18,660,099 USD 2194%
Operating Income (Loss) $1,145,497 USD -432%
Nonoperating Income (Expense) $11,768,132 USD -4026%
Income Tax Expense (Benefit) $1,013 USD
Net Income (Loss) Attributable to Parent $20,538,824 USD -2855%
Earnings Per Share, Basic -0.04 USD/shares -300%
Earnings Per Share, Diluted -0.04 USD/shares -300%

Balance Sheet

Label TTM Value / Value Unit Change %
Inventory, Net $35,437 USD
Assets, Current $2,403,129 USD 3788%
Assets $2,403,129 USD -64%
Accounts Payable, Current $1,060,889 USD
Accrued Liabilities, Current $266,930 USD
Liabilities, Current $13,860,506 USD 111%
Liabilities $13,870,407 USD 111%
Retained Earnings (Accumulated Deficit) $22,550,347 USD -47%
Stockholders' Equity Attributable to Parent $11,467,278 USD -1381%
Liabilities and Equity $2,403,129 USD -64%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,751,528 USD -808%
Net Cash Provided by (Used in) Financing Activities $3,094,438 USD 1251%
Common Stock, Shares Authorized 490,000,000 shares
Common Stock, Shares, Issued 49,525,970 shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,342,910 USD 3619%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1,948,271 USD 11678%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 100%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $11,078,116 USD 25%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%